UK’s CMA Fines Four On Nortriptyline
Accord, Alissa, Lexon And King Fined Over £3.4m In Total
Four firms – Accord, Alissa, Lexon and King – have been fined by the UK’s Competition and Markets Authority over price-fixing and information-sharing activities related to the supply of nortriptyline.
You may also be interested in...
CMA Sees Fine Over Nortriptyline Upheld In UK
The UK’s Competition and Markets Authority has welcomed a ruling upholding its finding that Lexon broke competition law in relation to nortriptyline, along with a connected £1.2m fine.
UK Court Declines To Back Phenytoin Fines
A UK appeals court has provided detailed guidance on how the country’s Competition and Markets Authority should evaluate unfair pricing, as part of a ruling that upholds a previous decision to overturn CMA fines of almost £90m ($112m) imposed on Pfizer and marketing partner Flynn Pharma over pricing for phenytoin sodium capsules.
Two Admit Collusion On UK Nortriptyline
Alissa Healthcare and King Pharmaceuticals have admitted colluding over UK supplies of nortriptyline to keep prices up, following an investigation launched by the country’s CMA.